Technology & Accuracy

Q4: How accurate is the Provandas breath test compared to existing methods?
A: In preliminary research, our AI-powered approach has achieved 100% sensitivity and 93% specificity for lung cancer detection, outperforming standard low-dose CT scans. This ensures fewer missed cases and minimizes unnecessary invasive follow-ups.

Q5: What makes Provandas’ technology unique?
A:

  • Mass spectrometry–based analysis captures the entire molecular spectrum instead of a few biomarkers.

  • AI algorithms trained on large datasets detect complex disease patterns.

  • Reusable sampling system reduces costs and environmental waste.

  • Adaptability: the same platform can later screen for neurological diseases and other cancers.

Q6: Is the test approved by the FDA?
A: Provandas is currently preparing for FDA registration and CLIA waiver as part of its 2026 commercialization phase. Pilot studies and validation trials are already underway.

Data & Ethics

Q13: How is patient data handled?
A: Provandas ensures strict data security and privacy, compliant with HIPAA and GDPR standards. Data is encrypted, anonymized, and used solely for diagnostic analysis and algorithm training.

Q14: Does the breath test replace a doctor’s diagnosis?
A: No — Provandas provides screening insights, not definitive diagnoses. Test results help guide physicians to recommend follow-up imaging or medical consultations when needed.

Q15: How soon will users receive their results?
A: Results are typically available within 48–72 hours after the sample reaches the lab, delivered securely through digital or mail reports.

Access & Deployment

Q7: Who can use Provandas tests?
A: Anyone at risk for lung cancer — including smokers, non-smokers with occupational exposure, or individuals with family history. The test is designed for home use, clinics, and mobile diagnostic units, ensuring equitable access worldwide.

Q8: What is the cost of each test?
A: Each breath test is priced at approximately $200, including sample collection, shipping, and analysis — less than one-tenth the cost of a typical CT scan. Despite the affordability, the company maintains a 45–55% gross margin through scalable design and efficient logistics.

Q9: Where is Provandas launching first?
A: The initial market rollout will begin in North America, followed by Europe and Asia. Long-term expansion includes partnerships in West Africa and other developing regions to address broader diagnostic access gaps.

About Provandas

Q1: What is Provandas?
A: Provandas is a health technology company revolutionizing lung cancer screening through AI-powered breath diagnostics. Using advanced mass spectrometry and machine learning, we detect chemical biomarkers in exhaled breath — providing a non-invasive, affordable, and accurate alternative to traditional methods like CT scans.

Q2: Why focus on lung cancer screening?
A: Lung cancer has one of the lowest survival rates (28%) mainly because it’s often detected too late. Current screening methods are expensive, invasive, and expose patients to radiation. Provandas addresses this unmet need by enabling early, safe, and accessible detection for everyone.

Q3: How does the Provandas test work?
A: Patients exhale into a compact, user-friendly breath sampler. The sample is securely sealed and shipped to our centralized laboratory, where it’s analyzed using high-resolution mass spectrometry. Our AI algorithm interprets the breath’s chemical profile to identify early signatures of lung cancer, producing personalized diagnostic report

Investment & Partnerships

Q10: What stage is Provandas currently in?
A: Provandas is in its Pre-Seed (Angel) phase, seeking $100,000 for 5% equity to finalize proof-of-concept and develop its proprietary sampler. The next Seed Round aims to raise $1.8M for FDA preparations and infrastructure development.

Q11: How can investors or partners get involved?
A: Interested parties can join Provandas’ investor network or request access to the Provandas Data Room for clinical evidence, patents, and projections. Contact: invest@provandas.com.

Q12: What are Provandas’ long-term goals?
A: Beyond lung cancer, Provandas aims to expand into:

  • Broad-spectrum cancer screening for adults aged 30+

  • Neurological diseases like Alzheimer’s detection

  • Predictive analytics for personalized healthcare

  • Drug discovery and precision medicine applications using breath data